Company intelligence / Profile preview

CancerVac

Melbourne, Victoria, Australia

Ownership: Private
Development stage: Other

Overview

CancerVac was an Australian biotechnology company dedicated to developing personalized cancer immunotherapies. Its core technology, CVac, utilized a dendritic cell-based vaccine approach to target Mucin 1 (MUC1), a protein frequently overexpressed in solid tumors such as ovarian and pancreatic cancer. The company successfully advanced its lead candidate into Phase 2 clinical trials, showing promise in extending progression-free survival in cancer patients. In 2004, CancerVac was acquired by Prima BioMed (now Immutep), which integrated the CVac platform into its oncology pipeline before eventually shifting focus toward LAG-3 therapeutics.

Therapeutic areas: Oncology
Modalities: Dendritic cell therapyVaccineCell therapy
Industry: Biotech

Partnerships

Austin Research Institute

Beyond the preview

Go deeper on CancerVac.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CancerVac.

Explore the full profile